CHR 5154

Drug Profile

CHR 5154

Alternative Names: 3117391; CHR-5154; CHR-5426; GSK 3117391

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator Chroma Therapeutics
  • Developer Chroma Therapeutics; GlaxoSmithKline
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in Rheumatoid arthritis in Poland (PO) (NCT02965599)
  • 22 Nov 2016 GlaxoSmithKline plans a phase II trial for Rheumatoid arthritis in Romania (NCT02965599)
  • 31 Aug 2013 Phase-I clinical trials in Rheumatoid arthritis (in volunteers) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top